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Abstract
Background Endovenous laser ablation is well recognized as
the first-line treatment for superficial venous reflux with var-
icose veins in adults. It is not widely reported and is not an
established practice in pediatric patients.
Objective To illustrate a variety of pediatric venous conditions
in which endovenous laser ablation can be utilized and to
demonstrate its feasibility and safety in children.
Materials and methods We conducted a retrospective review
of endovenous laser ablation procedures performed between
January 2007 and July 2014 at two large pediatric institutions.
Results We included 35 patients (17 males) who underwent
endovenous laser ablation to 43 veins. Median age at first treat-
ment was 14 years (range: 3–18 years). Median weight was
56 kg (range: 19–97 kg). Underlying diagnoses were common
venous malformation (15), Klippel–Trenaunay syndrome (8),
superficial venous reflux with varicose veins (5), verrucous
hemangioma-related phlebectasia (4), venous varix (2) and ar-
teriovenous fistula (1). The most common aim of treatment was
to facilitate sclerotherapy. Thirty-four patients had treatment in
the lower limbs and one patient in an upper limb. Ten of the
veins treated with endovenous laser ablation had an additional
procedure performed to close the vein. Complications attribut-
able to endovenous laser ablation occurred in two patients (6%).
One patient experienced post-procedural pain and one patient
developed a temporary sensory nerve injury. Median clinical
follow-up was 13 months (range: 28 days–5.7 years). The aim
of the treatment was achieved in 29 of the 35 (83%) patients.
Conclusion Endovenous laser ablation is technically feasible
and safe in children. It can be used in the management of a
range of pediatric venous diseases with good outcomes.
Keywords Children . Endovenous laser ablation . Klippel–
Trenaunay syndrome . Varicose veins . Venous malformation
Introduction
Since the first use of endoluminal laser energy was reported in
1999 [1], its clinical use has grown and it has been shown in
adults to be both safe and effective for the treatment of vari-
cose veins related to superficial venous incompetence [2, 3].
Endovenous laser ablation is now considered a first-line treat-
ment option for varicose veins related to superficial venous
reflux [4].
The use of endovenous laser ablation is not widely reported
and is not an established practice in pediatrics. There are, how-
ever, several venous disorders in children in which endovenous
laser ablation can play a useful role. We report our experience
utilizing endovenous laser ablation in children of various ages
to treat a spectrum of venous disorders including some that are
outside the indication for which the technique was originally
designed. We demonstrate the feasibility of endovenous laser
ablation in children, illustrate a variety of pediatric venous dis-
eases in which endovenous laser ablation can be successfully
utilized, and report on the safety of the technique.
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Materials and methods
Patients
We obtained institutional research ethics board approval for
this two-center retrospective observational study.We collected
data from two large pediatric institutions with both pediatric
vascular anomaly services and well-established pediatric in-
terventional radiology programs (The Hospital for Sick
Children, Toronto, Canada, and Great Ormond Street
Hospital for Children NHS Foundation Trust, London, UK).
We included all consecutive patients 0–18 years of age who
underwent endovenous laser ablation between January 2007
and July 2014. There were no exclusion criteria. We identified
these patients by searching each institution’s interventional
radiology database for the procedure “endovenous laser abla-
tion.”Data sources included the institutional picture archiving
and communication systems, prospectively collected dedicat-
ed interventional radiology databases and paper or electronic
patient charts.
Demographics recorded included age, weight at the time of
endovenous laser ablation and gender. We also recorded pre-
procedural diagnosis, symptoms and imaging findings.
Procedural data included aim of treatment, number and nature
of veins treated, endovenous laser ablation technique, addi-
tional endovascular procedures performed at the same
time as endovenous laser ablation and recovery time.
Post-procedural data collected included postoperative
imaging, complications, outcome and length of follow-
up. Complications were graded according the Society of
Interventional Radiology classification of complications
[5].
Endovenous laser ablation technique
Informed consent for endovenous laser ablation with or with-
out additional endovascular procedures was obtained prior to
all procedures. The procedures were performed under sterile
conditions in an angiography suite. Procedures were per-
formed under general anesthesia with continuous monitoring
of vital functions. The target vein was accessed percutaneous-
ly by using a micropuncture technique with US guidance. A 4-
French laser sheath was advanced over a 0.035-in. wire to the
intended start point of ablation. The wire was exchanged for
the laser fiber, ensuring the laser fiber tip remained covered by
the sheath. Tumescent fluid was injected around the entire
length of the target vein. The tumescent fluid used was 0.9%
sodium chloride solution in 37 procedures, and lactated
Ringer solution in 4 procedures. Lidocaine was added to the
fluid in six procedures early in the series; no local anesthetic
was used for the other procedures. Because of target vein
length, four veins required two access sites and one vein re-
quired three access sites. Where multiple access sites were
used, access was gained at all sites before administration of
tumescent fluid. An 810-nmDiode laser with 600-μm bare-tip
fiber was used. The endovenous laser ablation systems were
either Vari-Lase (Aquilant Interventional, Hampshire, UK) or
Diomed EVLT (AngioDynamics, New York, NY). The power
used was 10–14watts in continuousmodewith a pullback rate
of 1–2 mm/s. Immediately following the procedure, either
20–30 mmHg or 30–40 mmHg compression garments
were applied and worn for 6–12 weeks. Eight patients
received prophylactic peri-procedural anticoagulation;
five of these patients were known to be prothrombotic.
Endovenous laser ablation was preceded by venography
or venous outflow embolization and followed by sclero-
therapy in select cases.
Results
Thirty-five patients (17 males) underwent a total of 41
endovenous laser ablation procedures to treat 43 veins (more
than one vein was ablated at some procedures; Table 1).
Median age at first treatment was 14 years (range: 3–18 years).
Median weight at first procedure was 56.4 kg (range: 19.1–
96.9 kg). The patients were divided into and analyzed in four
groups according to the underlying diagnosis [6]: common
venous malformation in 15 patients, Klippel–Trenaunay syn-
drome in 8 patients, superficial venous reflux with varicose
veins in 5 patients, and a group for other miscellaneous
vascular disorders comprising verrucous hemangioma-
related phlebectasia in 4 patients, venous varix in 2
patients and arteriovenous fistula in 1 patient.
Endovenous laser ablation was performed in the lower
limbs in 34 patients (19 right, 14 left, 1 bilateral) and in
the right upper limb in 1 patient. Three patients required
more than one endovenous laser ablation procedure to
ablate the target vein.
In addition to endovenous laser ablation, adjunctive closure
techniques were used for 10 veins in 10 patients. Six of these
veins were embryonic veins; all were occluded with an
Amplatzer Vascular Plug (St. Jude Medical Inc., St. Paul,
MN) to close the intrafascial deep cephalic component, and
two of these had additional sclerotherapy with sodium
tetradacyl sulfate 3% foam. Three veins were greater saphe-
nous vein and one was a non-embryonal dysplastic vein; these
all had sclerotherapy with sodium tetradacyl sulfate foam. The
choice of adjunctive closure method was based on the inter-
vening radiologist’s preference.
Early in the series, eight patients were electively admitted
overnight post-procedure; in one of these cases, the admission
was extended to two nights for management of pain. Thirty-
three procedures were conducted in outpatients. The overall
aim of the treatment was achieved in 29 of the 35 (83%, 95%
confidence interval [CI] 70–95%) patients.
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Patients with common venous malformations
Eighteen lower-limb veins were ablated in 15 patients with
venous malformations (right in 8 patients, left in 7 patients)
(Table 1). In 12 patients, the aim of endovenous laser ablation
was to close the venous outflow from the lesion to enable safe
injection of sclerosant into the venous malformation (Fig. 1).
In two patients, endovenous laser ablation was performed in
the greater saphenous vein to manage venous thrombosis —
in one to prevent recurrence of distal massive thrombus,
which had formed at a previous sclerotherapy treatment, and
in the other to prevent thrombus propagation and pain after
thrombus developed following sclerotherapy. In one patient,
endovenous laser ablation of the short saphenous vein was
Fig. 1 Multifocal venous
malformations in a 16-year-old
girl. a Clinical photographs
demonstrate multifocal venous
malformation located in skin and
subcutaneous tissue at the knee.
Venous malformations were also
located in intramuscular tissues of
the upper and lower thigh (not
shown). b, c Ultrasound (b) and
axial contrast-enhanced T1-
weighted fat-saturated MRI (c) of
subcutaneous soft tissues on the
medial aspect of the knee show an
ectatic greater saphenous vein
(arrow) with connecting draining
veins (arrowheads) from the
subcutaneous component
(asterisk) of the skin venous
malformations. d Direct puncture
venogram of subcutaneous
venous malformation (asterisk)
shows direct communication with
the greater saphenous vein
(arrow). Endovenous laser
ablation of the greater saphenous
vein was performed. e Repeat
venogram of subcutaneous
venous malformation following
endovenous laser ablation of the
greater saphenous vein shows
reduced communication with the
greater saphenous vein, which
allowed for sclerotherapy of the
venous malformation. Following
endovenous laser ablation and
sclerotherapy, pain and medial
knee swelling improved and
selected skin venous
malformations became flatter and
paler
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performed to reduce symptoms of recurrent thrombophlebitis.
One vein required three separate endovenous laser ablation
procedures and one vein required two procedures to achieve
closure. Six patients had additional procedures to close the
ablated vein at the time of endovenous laser ablation:
four had sclerotherapy post-ablation and two underwent
pre-ablation endovascular occlusion with an Amplatzer
Vascular Plug IV. Three patients were temporarily
anticoagulated pre- and post-endovenous laser ablation:
one had underlying coagulopathy and two had a history
of recurrent superficial venous thrombosis.
The aim of the endovenous laser ablation was achieved in
13 of the 15 patients (87%). In both patients in whom the aim
of endovenous laser ablation was not achieved, it had been
performed to facilitate sclerotherapy. Neither patient went on
to have sclerotherapy: one had persistent symptoms and a
patent vein on ultrasound at 43 days post ablation; the other
underwent an attempt to perform sclerotherapy but had no
accessible channels and symptoms persisted. Despite achieve-
ment of the clinical aim of endovenous laser ablation in 13
patients, long-term vein closure, assessed at follow-up imag-
ing, was not always achieved. There was no imaging follow-
up in one patient after two endovenous laser ablations to a
single vein.
Patients with Klippel–Trenaunay syndrome
Eight patients with Klippel–Trenaunay syndrome (Table 1)
were treated with the aim of improvement of pain or
extremity swelling in five, cosmetic improvement of
varicosities in two and to facilitate sclerotherapy by
closing draining veins in one. Prior to endovenous laser
ablation, all patients underwent venography to prove patency
of the deep venous system and demonstrate anatomy of the
target veins.
One patient undergoing endovenous laser ablation to an
embryonic vein required two pullbacks of the laser to close
the vein adequately (Fig. 2). One patient required repeat
endovenous laser ablation of the greater saphenous vein be-
cause the lower end of the greater saphenous vein initially
remained patent. Three patients had endovascular placement
of an Amplatzer Vascular Plug II to close the intra-fascial deep
cephalic component of the embryonic vein and prevent sub-
sequent thromboembolism to the central veins. Two of these
also underwent sclerotherapy with sodium tetradecyl sulfate
(STS) foam (Sotradecol; Bioniche Pharma USA, Lake Forest,
IL) at the time of endovenous laser ablation. Sclerotherapy
with STS foam was undertaken in one patient 49 days post
endovenous laser ablation to treat residual patency of the treat-
ed vein. Four patients received prophylactic peri-procedural
anticoagulation. One patient had an inferior vena cava (IVC)
filter placed at the same procedure as the endovenous
laser ablation.
The aim of endovenous laser ablation was achieved in sev-
en of the eight patients (88%) and partially achieved in one
patient, who showed some improvement in pain and swelling
with residual patency of the treated vein on follow-up
imaging.
Patients with superficial venous reflux with varicose veins
Five patients were treated for varicose veins (Table 1). Prior to
endovenous laser ablation treatment, all patients had Duplex
ultrasonography demonstrating superficial venous reflux. A
total of seven greater saphenous veins were ablated.
Endovenous laser ablation was commenced 2 cm below
the sapheno-femoral junction in keeping with adult treat-
ment recommendations [7]. In one patient endovenous laser
ablation was done bilaterally; this patient had three veins
(bilateral greater saphenous and an accessory greater
saphenous vein) ablated over two endovenous laser ab-
lation procedures. No adjunctive therapy was used at
the time of treatment and none of these patients required
anticoagulation.
The aim of the endovenous laser ablation was
achieved in three of the five patients (60%). In the
two patients where symptom improvement was not
achieved, however, follow-up imaging did show vein
closure. In one of these patients there was partial reduction
in varicosities and in the other there was no improvement to
the varicosity-related pain.
Patients with miscellaneous anomalies
There were seven other patients, with a range of underlying
diagnoses treated, with nine veins treated with endovenous
laser ablation in eight procedures (Table 1). In one patient,
endovenous laser ablation was used to close the draining vein
of an arteriovenous fistula to facilitate subsequent direct glue
embolization of the fistula (Fig. 3). Two patients were treated
to reduce pain and swelling and to facilitate sclerotherapy of
large superficial varicosities. Four patients with verrucous
hemangiomas were treated, with the aim to facilitate sclero-
therapy of verrucous hemangioma associated phlebectasia in
two, facilitate surgical excision of the lesion in one, provide
cosmetic improvement in one and reduce symptoms of pain
and swelling in three (there was more than one indication in
some patients). One patient with verrucous-hemangioma-
related phlebectasia had two procedures: the first was to close
an associated embryonic vein; however the patient remained
symptomatic and was found to have a new enlarged
embryonic vein, so this was closed at the second pro-
cedure. None of the treated veins required adjunctive
closure techniques at the time of the endovenous laser
ablation. Only the patient with the arteriovenous fistula
received intra-procedural anticoagulation.
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The aim of the endovenous laser ablation was achieved in
six of the seven patients (86%). The patient in whom
the aim of treatment was not achieved had a non-
embryonic dysplastic vein partially closed at follow-up
imaging; however symptoms of pain and swelling only
resolved after the vein was ligated 199 days post
endovenous laser ablation. In the six patients in whom
the aim of treatment was achieved at follow-up, the
treated veins were closed in two patients and partially
closed in the remainder.
Complications
There were six complications following five procedures in
five patients. Of these, two were directly attributable to the
endovenous laser ablation procedure (6%, 95% confidence
interval [CI] 0–13%). One was an episode of localized pain
that resulted in extension of the patient’s hospital stay by 1
night (Society of Interventional Radiology category B, i.e.
requiring nominal therapy with no consequence; Table 1).
The other was a temporary cutaneous sensory nerve injury
Fig. 2 Klippel–Trenaunay syndrome in a 15-year-old girl. a Clinical
photographs demonstrate knee swelling (from subcutaneous venous
malformation). Ink mark on the cutaneous “geographic capillary
malformation” was done by the surgeon prior to local excision of
lymphatic vesicles on capillary malformation. b–e Direct puncture
venograms of subcutaneous venous malformation on anterior knee. A
large central vein (asterisks) is seen draining into the popliteal vein
(arrows) when tourniquet is applied across lower thigh on both the
frontal (b) and oblique (c) projections. With thigh tourniquet released
(d) prompt drainage is seen superiorly from venous malformation into
the embryonic vein in the anterior thigh (arrowhead). Following
endovenous laser ablation of the embryonic vein, the venous outflow
from the venous malformation into the embryonic vein is reduced,
allowing for more effective sclerotherapy of the venous malformation (e)
Pediatr Radiol
(Society of Interventional Radiology category A, i.e. requiring
no therapy and with no consequence). This presented as
sensory blunting noted at the first clinical follow-up 47 days
post endovenous laser ablation to facilitate sclerotherapy in a
Fig. 3 Arteriovenous fistula in a 16-year-old boy. a Arteriogram
confirms arteriovenous fistula (arrow) supplied by tibial arteries with
drainage into the greater saphenous vein (arrowhead). b A bony defect
in the tibia (arrow) caused by the arteriovenous fistula. c Direct
venography of greater saphenous vein shows venous end of the
arteriovenous fistula (at the tibial bony defect) draining into the greater
saphenous vein (arrowhead). Measurements of bony defect and vein
were performed and endovenous laser ablation was then undertaken to
occlude the greater saphenous vein. d Contrast agent injection following
direct needle puncture of the venous end of the arteriovenous fistula
(arrow) immediately after endovenous laser ablation was followed by
embolization with glue. e Repeat arteriogram (immediately after
endovenous laser ablation and glue embolization) confirms
arteriovenous fistula closure
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patient with a venous malformation and subsequently re-
solved. The remaining complications were clinically deter-
mined to be unrelated directly to the endovenous laser ablation
procedure and included: one temporary sensory nerve injury
(Society of Interventional Radiology category A), which pre-
sented as altered skin sensation in distribution of sclerotherapy
treatment, not endovenous laser ablation treatment; one 1-cm2
area of ulceration in the popliteal fossa following endovenous
laser ablation of an embryonic vein (Society of Interventional
Radiology category B), which based on the location was
thought to be caused by reflux of STS; one IVC perforation
by the strut of an IVC filter placed at the same time as the
endovenous laser ablation treatment (Society of Interventional
Radiology category C, i.e. requiring therapy or minor hospi-
talization <48 h); and one episode of musculoskeletal chest
pain (Society of Interventional Radiology category B), which
presented to the emergency department and required a workup
including a negative CT pulmonary angiogram.
Discussion
Endovenous laser ablation delivers thermal energy from a
point source at the tip of the laser fiber in the lumen of the
vein, causing vessel wall heating. Several mechanisms result
in an increase in vein wall temperature, including the direct
contact of the fiber tip, the optical-thermal interaction of laser
light and surrounding tissues, the heat flow from carbonized
blood around the fiber tip and the heat transfer from steam
bubbles produced during endovenous laser ablation [8]. This
results in collagen contraction and denudement of the endo-
thelium, stimulating vein wall thickening with eventual lumi-
nal contraction and vein fibrosis. The laser energy is distrib-
uted along the length of the vein to be treated by retracting the
laser fiber along the vein. This results in non-thrombotic ves-
sel occlusion [3]. It is now understood that the efficacy of
endovenous laser ablation is influenced less by the target chro-
mophore (hemoglobin) and the wavelength of the laser light
than was previously thought. Although laser energy at 810 nm
wavelength, delivered via a 600 μm laser fiber, is widely used
in clinical practice in adults, it is recognized that many wave-
lengths between 810 nm and 1,470 nm are effective in vein
obliteration [9]. The efficacy of endovenous laser ablation is
determined by several factors including the laser power (i.e.
the fluence rate and not the laser energy), the pullback velocity
and the vein diameter [9].
The literature to date regarding endovenous laser ablation
has focused on its applications in adults, in whom endovenous
laser ablation has been demonstrated to be effective and safe
in the treatment of greater saphenous vein reflux with a long-
term occlusion rate of 93% [3]. Clinical outcomes from
endovenous laser ablation and surgical treatment for varicose
veins related to sapheno-femoral reflux are in equipoise [2, 10,
11], and endovenous laser ablation has become the first-line
treatment option for varicose veins [4].
There is a paucity of reports of the use of endovenous
laser ablation in children [12, 13]. Interstitial laser ablation
for vascular malformations using a neodymium:yttrium
aluminum garnet laser was reported as early as 1986
[14]. Subsequently a cohort of six children with venous
malformations was treated using an intralesional diode la-
ser with good outcomes and no major complications [12].
More recently the successful use of endovenous laser ab-
lation with a diode laser was reported in treating the em-
bryonic marginal venous system in four children weighing
less than 20 kg with Klippel–Trenaunay syndrome [13].
Our study combines data from two major pediatric tertiary
referral hospitals and includes 35 patients, with the aim of
the endovenous laser ablation being achieved in 29 (83%).
Although to the best of our knowledge this is the largest
published cohort of children undergoing endovenous laser
ablation, in our series the 95% confidence interval is wide,
ranging 70–95%.
Our results highlight differences that need to be taken into
consideration when undertaking endovenous laser ablation in
children as a result of both the variable venous diseases en-
countered and the specific requirements of pediatrics. For ex-
ample, we found that endovenous laser ablation can be a use-
ful treatment adjunct in patients undergoing intralesional
sclerotherapy to treat soft-tissue venous malformations where
the outflow control from the venous malformation cannot be
achieved by simple measures such as an external tourniquet.
In such cases endovenous laser ablation, by isolating the ve-
nous malformation from its venous outflow, allows for more
effective intralesional sclerotherapy, as in 14 of our patients.
Another example included in the cohort is a patient in whom
endovenous laser ablation was used for closure of the venous
outflow from an arteriovenous fistula. Closure of the vein
allowed for subsequent glue embolization of the fistula. This
novel application of endovenous laser ablation highlights the
versatility of the treatment modality; however based upon a
single patient we cannot comment on how successful or useful
endovenous laser ablation may be for other such cases.
Children with Klippel–Trenaunay syndrome are a distinct
subgroup because of their variable venous anatomy and pre-
disposition to venothromboembolic events [15–17]. In these
children there is typically a coexistent prominent marginal
venous system and a deep venous system. When undertaking
endovenous laser ablation of an extremity embryonic margin-
al vein, venographic assessment of both the deep venous sys-
tem and the embryonic veins should be undertaken prior to
endovenous laser ablation. Establishing patency and continu-
ity of the deep venous system is mandatory before treatment
of the embryonic vein is undertaken [16, 18]. In all our pa-
tients with Klippel–Trenaunay syndrome, pre-endovenous la-
ser ablation venography was performed using a technique
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similar to that described by Alomari [16]. The embryonic
marginal venous system is located within the lateral aspect
of the extremity and is usually composed of valveless super-
ficial sometimes thick-walled ectatic veins, which predispose
to venous stasis and thromboembolism, particularly in the
post-procedural period [16, 17]. Therefore these patients
should have their coagulation parameters checked prior to
endovenous laser ablation. Peri-procedural anticoagulation,
under the supervision of a hematologist, should be considered
because of the higher risk of venous thromboembolism in this
population, particularly when procedures are expected to be
complex and lengthy. We placed one IVC filter prior to
endovenous laser ablation in one patient because of the higher
risk of thromboembolism in that patient.
Planning the site for venous access is important when un-
dertaking endovenous laser ablation in children because of the
variable nature of the venous diseases encountered in pediat-
rics. For endovenous laser ablation treatment for varicose
veins related to sapheno-femoral reflux, the preferred point
of the greater saphenous vein puncture is just below the knee,
as in adults, with endovenous laser ablation commencing 2 cm
below the sapheno-femoral junction [7]. When ablating long
or tortuous vein segments, as in five of our endovenous laser
ablation treated veins, more than one venous entry site might
be required. Vein tortuosity is considered by some interven-
tional radiologists to be a contraindication to endovenous laser
ablation [19]. This is because the relatively stiff laser fiber
might not track well along the tortuous veins. However this
was not found to be to be a problem in any of the patients in
this cohort. Atasoy [19] reported 98% technical success when
performing endovenous laser ablation in very large and tortu-
ous great saphenous veins in adults. The author achieved this
by using US-guided catheterization with support from the
straight catheter of the laser and by using multiple access
points when the former failed. This was carried out to avoid
navigating tortuous vessels with angled-tip catheters, which
can be time-consuming and risky for vasoconstriction or vein
rupture [19]. Atasoy [19] suggested that tortuosity is not a
problem for an interventionalist who has adequate US-
guided technical skill. Following our experience, we recom-
mend that all venous access be gained prior to injection of
tumescence.
Tumescent fluid around the vein is as important in children
as it is in adults undergoing endovenous laser ablation. The
fluid serves three purposes. It compresses and reduces the
diameter of the vein to be treated by apposing the vein wall
closer to the laser fiber, thereby optimizing circumferential
vein wall heating. Second, it acts as a “heat sink,” protecting
adjacent tissues from thermal damage. Third, it can provide
analgesia to the region being treated when local analgesia is
added to the tumescent fluid [3]. In adults this is often a crys-
talloid fluid mixed with a local anesthetic agent, for example
500 mL saline, 25 mL 2% lidocaine and 10 mL sodium
bicarbonate 8.4% [7]. In keeping with previous reports, [13]
all the children in our cohort were treated under general anes-
thesia. When children are under general analgesia for the pro-
cedure, in keeping with the technique also reported by King
et al. [13], we recommend that no local analgesia be added to
the tumescent fluid.
As we encountered, there can be some technical problems
in achieving and maintaining the tumescence for endovenous
laser ablation. This can be problematic in patients with
Klippel–Trenaunay syndrome when treating the embryonic
marginal vein. However this vein is often surrounded by nu-
merous small veins and does not have a surrounding fascial
envelope. When fluid is injected around the vein there is often
relatively quick dispersion of the fluid, which sometimes has
to be reinjected to maintain adequate tumescence.
Compression post endovenous laser ablation for the treat-
ment of varicose veins has been reported to reduce pain and
improve function [20]; however there is little evidence upon
which to base recommendations regarding the usage of com-
pression stockings [21]. Although the use of compression post
endovenous laser ablation has been reported in children, it was
used for a short period of only 5 days post endovenous laser
ablation [13]. In our cohort compression garments were worn
by all our patients (using either 20–30 mmHg or 30–
40 mmHg compression) for at least 6 weeks following
endovenous laser ablation.We found that compliance in stock-
ing wearing over the 6 weeks was good in all except two
patients, both of whom required more than one endovenous
laser ablation treatment to the same vein. Among children with
venous diseases, compression garments can provide signifi-
cant symptomatic relief for many patients and might prevent
progressive expansion of venous lesions [22]. In toddlers there
might be some practical challenges in obtaining a well-fitted
compression stocking and therefore alternatives might be re-
quired. We recommend the temporary use of compression fol-
lowing endovenous laser ablation in children.
Complications of endovenous laser ablation are rare and
include skin burns, nerve injury, arteriovenous fistula,
endothermal heat-induced thrombosis and deep venous
thrombosis [4]. Lower-extremity bruising and limb tightness
are commonly reported after endovenous laser ablation, in
24% and 90% of patients, respectively [3]. No major compli-
cations have been reported in the few published pediatric
cases to date [12, 13]. In our cohort, minor complications from
endovenous laser ablation occurred in 2 of 35 patients
(prolonged pain and a transient sensory nerve dysfunction).
This gives a complications rate of 6% with a 95% confidence
interval ranging 0–13%.Nerve injury can occur because of the
proximity of nerves to ablated veins. Nerve injuries are report-
ed in <1% of endovenous laser ablations [23]. The saphenous
nerve is at risk of injury in the mid- to distal calf when the
greater saphenous vein is ablated. The sural nerve is at greatest
risk of injury in the distal calf where it is close to a treated
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short saphenous vein. Injury to these nerves results in cutane-
ous paresthesia, which is usually transient. The common pe-
roneal nerve is a motor and sensory cutaneous nerve that de-
scends within the lateral popliteal fossa, posterior to the head
of the fibula, and is at greatest risk of injury in the region of the
sapheno-popliteal junction [4]. Tumescence plays an impor-
tant role in protection against nerve injury. Self-limiting local
paresthesia lasting up to 3 weeks has been reported to have an
incidence of 36.5% without tumescence [24].
In addition to endovenous laser ablation, there are numer-
ous other methods to achieve vein closure. These include coil
or vascular occlusion plug placement and adjuvant sclerother-
apy. This study does not compare the outcomes of these var-
ious treatment modalities and a detailed discussion of these
alternative techniques is beyond the scope of this report. It
should, however, be noted that vessels are often too large for
closure with standard coils and sometimes even vascular oc-
clusion plugs; in addition, to perform effective sclerotherapy
of such veins, larger volumes of sclerosant might be required
than are permitted in small patients, risking impairment of
renal function [25]. Occasionally, these methods might be
required as an adjunct to endovenous laser ablation, as in 10
of our patients. When long veins need to be closed, such as the
embryonic lateral marginal vein, the endovascular placement
of sclerosant, coils or plugs might be needed to close the upper
deep intrafacial segments of the vein before laser ablating the
extrafascial component of the vein. Adequate tumescence is
not possible in such deep locations; this increases the risk of
failure of endovenous laser ablation and of damage to struc-
tures surrounding the vein. After the intrafascial segments of
the vein are closed, endovenous laser ablation with tumes-
cence can be safely undertaken to treat the extrafascial super-
ficial segments of the vein. Another reason that adjunctive
techniques are used to close veins was to minimize the risk
of subsequent thromboembolism.
Although in this cohort endovenous laser ablation was
found to be useful, there are some considerations regarding
how generalizable the results are. The study was conducted at
two large tertiary care institutions serving as regional referral
centers for the management of children with vascular anoma-
lies. As such, there is significant accumulated experience in
the nuances of performing interventions in such patients. In
addition, to undertake endovenous laser ablation, a disposable
laser fiber and sheath and a laser source are required. A de-
tailed cost analysis of the procedure is beyond the scope of the
study. The disposable fiber and sheath kit costs approximately
CAD $440. However the laser generator costs about CAD
$30,000. Although laser ablation can be used for a variety of
applications, such as osteoid osteoma ablation [26], the price
of endovenous laser ablation might be considered high for
low-volume institutions. For these reasons, the results present-
ed here are generalizable only to institutions with a similar
referral base and experience, whereas centers less used to
managing patients with such pathologies might find the tech-
nique less useful.
This study has some other limitations that must be ac-
knowledged. This is a retrospective review of a small cohort
of children with limited patient numbers in each diagnostic
category of venous disease. The duration of follow-up was
limited and therefore conclusions regarding the durability of
treatment cannot be made.
Conclusion
Endovenous laser ablation expands the range of treatment
options available for the management of a variety of venous
anomalies in children. This study adds strength to previously
published data confirming that endovenous laser ablation is
feasible in children with an expected complication rate of 0–
13%. In this cohort of patients, the aim of treatment was
achieved in 83% of patients; however given the limitation of
this and other studies of endovenous laser ablation in children,
assessment of the technique in a larger number of children in
whom there is longer-term follow-up is required.
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